Vincent Charlon

TL;DR: An endothelin-receptor antagonist, bosentan, significantly lowered blood pressure in patients with essential hypertension, suggesting thatendothelin may contribute to elevated blood pressure to patients with mild-to-moderate essential hypertension.

TL;DR: The findings suggest that the clinical responses to endothelin antagonism with bosentan in patients with severe chronic heart failure may be dependent on the duration of treatment.

TL;DR: Ro 42-5892 (Ro) is a new renin inhibitor that has been shown to be an orally effective compound in primates and in the first exploratory studies in humans and therefore the present study was designed to evaluate the antihypertensive efficacy of the compound in a double-blind, placebo-controlled trial.

TL;DR: Overall, mibefradil was better tolerated than amlodipine and nifedipine SR/GITS and was as well tolerated as diltiazem SR/CD and the results of this comprehensive safety analysis indicate that treatment with the recommended doses of mibfradil is well tolerated and safe.

TL;DR: Early clinical experience with bosentan has confirmed some benefits on hemodynamic parameters in patients with CHF, and its role in slowing the progression of the disease and improving survival remains to be elucidated.